Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SAN DIEGO , March 5, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... announced today that its fourth quarter and full ... Monday, March 16, 2015, before the market opens ... management will host a conference call to discuss ...
(Date:3/5/2015)... TÜBINGEN, Deutschland, 5. März 2015  Die ... das deutsche biopharmazeutische Unternehmen CureVac geben heute ... (52 Millionen US-Dollar) in CureVac investiert. CureVac ... angewandten Messenger-RNA (mRNA). Auf Basis dieses Moleküls ... von Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... WHIPPANY, N.J. , March 5, 2015 ... million dollars to the Conquer Cancer Foundation of the ... a cutting edge health information technology platform designed to ... people living with cancer.  "Bayer is ... in their efforts to leverage Big Data to help ...
Breaking Medicine Technology:Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3
... , JERUSALEM , ... TEVA ) announced today the availability of new resources to ... designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] ... failure due to inadequate secretion of normal endogenous growth hormone. ...
... Feb. 2 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA), ... care program in eastern Ohio and northern West ... 30-day supply of more than 300 generic prescription medications for only ... program for as low as $83 a month, this ...
Cached Medicine Technology:Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6HealthWarehouse.com and PrimaryCareOne Form Partnership to Provide Low Cost Prescription Medications to Patients 2HealthWarehouse.com and PrimaryCareOne Form Partnership to Provide Low Cost Prescription Medications to Patients 3HealthWarehouse.com and PrimaryCareOne Form Partnership to Provide Low Cost Prescription Medications to Patients 4
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 Los Angeles ... a special promotion for Zoom whitening. Zoom is a special ... a professional setting. Unlike other teeth whitening treatments, Zoom does ... and free of stains. For a limited time, Dr. Ghasri ... discount from the usual price of $650 and allows patients ...
(Date:3/6/2015)... 2015 Fluid Running® Owner, Jennifer Conroyd, ... the Fluid Running® method 3 years ago ... marathon. She hit upon the trifecta of combining matched-bpm ... a maximum-resistance, deep water running technique. She not only ... water running workout that made the experience both enjoyable ...
(Date:3/6/2015)... The Public Health Accreditation Board ... status to seven more health departments. This week’s decisions ... people can now be assured that their health departments ... of their communities. , Public health departments play a ... people and communities. Across the nation, health departments provide ...
(Date:3/5/2015)... March 06, 2015 The global digital PCR (dPCR) ... at CAGR of 7.8% from 2014 to 2019. , The global ... a CAGR of 7.8% from 2014 to 2019. Although the mature ... shares in the digital PCR (dPCR) and qPCR market the Asia-Pacific ... in the forecast period. The growth of the digital PCR (dPCR) ...
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned a verdict ... plaintiff Coleen M. Perry a total of $5.7 million for ... mesh sling device, manufactured by Ethicon, Inc., a subsidiary of ... at Wagstaff & Cartmell in Kansas City, Mo., ... Rich Freese and Tim Goss of Freese & Goss ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2
... was recently introduced at the Summer American ... for the treatment of mild-to-moderate atopic dermatitis ... LLC, the marketers of Locoid Lipocream (hydrocortisone ... corticosteroids, recently launched the new product to ...
... AIDS experts at Johns Hopkins say they have compelling evidence ... decades show extremely low levels of the virus in their ... even without treatment, probably do so because of the strength ... of HIV that infected them in the first place. ...
... INC., announced today,that the wireless version of its ... Drug Administration (FDA) 510(k) clearance., (Logo: ... MR Infusion System enables the clinician to,control a ... from both inside and outside the scan room. ...
... Inc.,s parent,company, Team Finance LLC (the "Company") today ... 2008., The Company previously announced the decision ... substantially completed the disposal,of this business line during ... accounting guidance, the results of the anesthesia management,business ...
... Prevent,Another Blood Crisis, Allow More New Yorkers To Give, ... NEW YORK, Aug. 11 With New York ... City Councilman Eric Gioia,(D-Queens), Chairman of the City Council ... Blood Center called for city,aid in expanding the successful ...
... 11 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... to offer, subject to market and other conditions, ... due 2013 and,American Depositary Shares, or ADSs, which ... the notes offering pursuant to ADS,issuance and repurchase ...
Cached Medicine News:Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 2Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 3Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 4Health News:Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs 2Health News:Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs 3Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 2Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 3Health News:Team Finance LLC Announces Second Quarter 2008 Results 2Health News:Team Finance LLC Announces Second Quarter 2008 Results 3Health News:Team Finance LLC Announces Second Quarter 2008 Results 4Health News:Team Finance LLC Announces Second Quarter 2008 Results 5Health News:Team Finance LLC Announces Second Quarter 2008 Results 6Health News:Team Finance LLC Announces Second Quarter 2008 Results 7Health News:Team Finance LLC Announces Second Quarter 2008 Results 8Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 3Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 2Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 3Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 4
... The LABOTECH is an automated ... automating immunoenzymatic microplate techniques. Open ... adaptable to many manufacturers' microplate ... to traditional R.I.A. and I.F.A. ...
... Micro Plate Processor is a precise, ... Analyzer. It has been designed for ... can be customised according to the ... Processor is able to process automatically ...
The GEM OPL CO-Oximeter provides comprehensive oxygenation status in an easy-to-use, portable manner. The GEM OPL is the ideal solution for laboratory or point-of-care CO-Oximetry testing....
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
Medicine Products: